[Use of a GnRH analogue (leuprorelin) in the therapy of endometriosis].
BACKGROUND
Endometriosis is undoubtedly an extremely complex disease from both a diagnostic and therapeutic point of view. The finding that the continuous administration of GnRH analogs suppresses gonadotropin release by the hupophysis, thus blocking ovary function, has promoted researchers to use these drugs in the treatment of endometriosis.


OBJECTIVE
Having reviewed the data reported in the literature, the authors selected from the numerous drugs used to resolve implants (oestroprogestogens, danazol, progestogens, clomiphene citrata, GnRH analogs), a GnRH analog with a depot action known as leuprorelin (D-Leu6-Pro9-NH-Ethylamide).


METHODS
This drug was administered to 98 patients suffering from endometriosis at a dose of one intramuscular phial every 30 days for six months.


CONCLUSIONS
The results obtained (complete resolution of disease in 610.2% of cases, partial remission in 30.6% of cases, transient improvement in 9.2% of cases owing to reduced patient compliance, percentage of pregnancies after treatment 12%), allow the authors to conclude that the use of a GnRH antagonist, like leuprorelin, owing to its efficacy and good tolerability, represents a valid alternative to oestroprogestogens and Danazol in the treatment of implants and the symptoms of endometriosis.
Grio
R
R
Dipartimento di Discipline, Ginecologiche e Ostetriche, Università degli Studi, Torino.
Geranio
R
R
Porpiglia
M
M
Leidi
L
L
Piacentino
R
R
D000328:Adult; D004305:Dose-Response Relationship, Drug; D004715:Endometriosis / Q000188:drug therapy*; D005260:Female; D007987:Gonadotropin-Releasing Hormone / Q000031:analogs & derivatives*; D006062:Gonadotropins / Q000009:adverse effects; D006801:Humans; D016729:Leuprolide / Q000008:administration & dosage*; D008875:Middle Aged
D006062:Gonadotropins; D007987:Gonadotropin-Releasing Hormone; D016729:Leuprolide